Industry news
Pfizer terminates agreement with Catalyst Biosciences
In 2008, Catalyst Biosciences signed a $500 million-plus deal to develop Factor VIIa therapies for hemophilia with Pfizer. However Pfizer is now breaking the pact it inherited from Wyeth.